OncoMatch/Clinical Trials/NCT06484361
PET/MRI to Stage Prostate Cancer Patients
Is NCT06484361 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including 68Ga-PSMA and 68Ga-RM2 for prostate cancer.
Treatment: 68Ga-PSMA · 68Ga-RM2 — The main goal of this phase II clinical trial is to define a novel approach of staging prostate cancer (PCa) patients by using a fully integrated positron emission tomography/ magnetic resonance imaging (PET/MRI) system with 68Ga-prostate specifica membrane antigen (PSMA) and 68Ga-RM2 (bombesin antagonist). 50 patients with biopsy proven PCa will be studied by PET/MRI with 68Ga-PSMA and with 68Ga-RM2 and then will undergo prostatectomy and pelvic lymphadenectomy.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Prostate Cancer
Disease stage
Grade: high
Demographics
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06484361 currently recruiting?
Yes, this trial is currently recruiting patients.
Is this trial open to female patients?
No. This trial enrolls male patients only.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages